AIM ImmunoTech (AIM) 10-Q 12 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 01, 2015
Document and Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,015
Entity Registrant Name	HEMISPHERX BIOPHARMA INC
Entity Central Index Key	946,644
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding (shares)		246,886,840

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,842	$ 2,156
Marketable securities	13,872	13,952
Inventory-work in process	1,009	0
Prepaid expenses and other current assets	338	399
Total current assets	17,061	16,507
Property and equipment, net	11,720	4,601
Patent and trademark rights, net	951	861
Construction in progress	0	7,337
Other assets	134	134
Total assets	29,866	29,440
Current liabilities:
Accounts payable	1,598	2,081
Accrued expenses	1,497	2,333
Current portion of capital lease	7	22
Total current liabilities	$ 3,102	$ 4,436
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, par value $0.01 per share, authorized 5,000,000; issued and outstanding; none	$ 0	$ 0
Common stock, par value $0.001 per share, authorized 350,000,000 shares; issued and outstanding 245,483,480 and 204,004,818, respectively	245	204
Additional paid-in capital	312,764	302,729
Accumulated other comprehensive loss	(186)	(160)
Accumulated deficit	(286,059)	(277,769)
Total stockholders’ equity	26,764	25,004
Total liabilities and stockholders’ equity	$ 29,866	$ 29,440

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value per share (usd per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Common stock, authorized shares	350,000,000	350,000,000
Common stock, issued	245,483,480	204,004,818
Common stock, outstanding	245,483,480	204,004,818

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Clinical treatment programs	$ 47	$ 36	$ 83	$ 112
Total revenues	47	36	83	112
Costs and expenses:
Production costs	507	294	879	617
Research and development	2,439	2,330	5,113	4,656
General and administrative	2,002	2,497	3,915	5,036
Total costs and expenses	4,948	5,121	9,907	10,309
Operating loss	(4,901)	(5,085)	(9,824)	(10,197)
Interest expense	0	(3)	(2)	(6)
Interest and other income/expense	56	131	162	284
Redeemable warrants valuation adjustment	0	1	0	1
Gain from sale of income tax net operating losses	0	0	1,374	1,126
Net loss	(4,845)	(4,956)	(8,290)	(8,792)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	(137)	147	(26)	168
Net comprehensive loss	$ (4,982)	$ (4,809)	$ (8,316)	$ (8,624)
Basic and diluted loss per share (usd per share)	$ (0.02)	$ (0.03)	$ (0.04)	$ (0.05)
Weighted average shares outstanding, basic and diluted (shares)	236,149,999	185,749,722	224,954,200	181,265,253

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - 6 months ended Jun. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance, Common Stock (Shares) at Dec. 31, 2014		204,004,818
Balance at Dec. 31, 2014	$ 25,004	$ 204	$ 302,729	$ (160)	$ (277,769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares to settle accounts payable (shares)		2,558,779
Shares to settle accounts payable	672	$ 2	670
Equity-based compensation	111		111
Stock sold at the market (shares)		38,919,883
Stock sold at the market	9,293	$ 39	9,254
Net comprehensive loss	(8,316)			(26)	(8,290)
Balance, Common Stock (Shares) at Jun. 30, 2015		245,483,480
Balance at Jun. 30, 2015	$ 26,764	$ 245	$ 312,764	$ (186)	$ (286,059)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Stockholders' Equity [Abstract]
Common stock, par value (usd per share)	$ 0.001	$ 0.001

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (8,290)	$ (8,792)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	458	332
Amortization and abandonment of patent and trademark rights	79	276
Redeemable warrants valuation adjustment	0	(1)
Equity-based compensation	111	198
Change in assets and liabilities:
Inventories	(1,009)	0
Prepaid expenses and other current assets	61	112
Accounts payable	189	238
Accrued expenses	(836)	1,431
Net cash used in operating activities	(9,237)	(6,206)
Cash flows from investing activities:
Purchase of property, equipment and construction in progress	(240)	(266)
Additions to patent and trademark rights	(169)	(120)
Deposits on capital leases refunded	0	2
Sales and maturities of short-term and long-term marketable securities	54	(36)
Net cash used in investing activities	(355)	(420)
Cash flows from financing activities:
Payments on capital leases	(15)	(18)
Proceeds from sale of stock, net of issuance costs	9,293	8,458
Net cash provided by financing activities	9,278	8,440
Net (decrease) increase in cash and cash equivalents	(314)	1,814
Cash and cash equivalents at beginning of period	2,156	803
Cash and cash equivalents at end of period	1,842	2,617
Supplemental disclosures of non-cash investing and financing cash flow information:
Issuance of common stock for accounts payable	672	38
Unrealized (loss) gain on marketable securities	(26)	168
Supplemental disclosure of cash flow information:
Cash paid for interest expense	$ (2)	$ (9)

Basis Of Presentation

Basis Of Presentation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis Of Presentation	Basis Of Presentation The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries (collectively, “Hemispherx”, “Company”, “we or “us”). The Company has three domestic subsidiaries: BioPro Corp., BioAegean Corp. and Core Biotech Corp., all of which are incorporated in Delaware and are dormant. The Company also has a foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., which was established in Belgium in 1998. All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of Management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year. The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2014 and 2013, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 17,228,280 and 23,730,334 shares for the six months ended June 30, 2015 and 2014, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

Equity-Based Compensation

Equity-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity-Based Compensation	Equity-Based Compensation The fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation model. Expected volatility is based on the historical volatility of the price of the Company’s stock. The risk-free interest rate is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate expected dividend yield, expected life and forfeiture rates. There were 800,000 and 855,000 options or equity warrants granted in the six months ended June 30, 2015 and 2014, respectively. Stock option for employees' activity during the six months ended June 30, 2015 is as follows: Stock option activity for employees: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2015 11,287,888 $ 1.64 4.61 $ — Granted 800,000 0.25 — — Forfeited (565,000 ) 1.75 — — Outstanding June 30, 2015 11,522,888 $ 1.54 4.71 $ — Vested and expected to vest June 30, 2015 11,522,888 $ 1.54 4.71 $ — Exercisable June 30, 2015 10,639,853 $ 1.60 4.17 $ — Unvested stock option activity for employees: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2015 710,594 $ 1.38 8.76 $ — Granted 800,000 0.25 — — Vested (627,559 ) 0.97 — — Forfeited — — — — Outstanding June 30, 2015 883,035 $ 0.65 8.97 $ — Stock option activity for non-employees: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2015 3,800,000 $ 1.36 4.75 $ — Granted — — — — Exercised — — — — Forfeited (327,000 ) 1.75 — — Outstanding June 30, 2015 3,473,000 $ 1.32 4.65 $ — Vested and expected to vest June 30, 2015 3,473,000 $ 1.32 4.65 $ — Exercisable June 30, 2015 3,464,667 $ 1.56 4.29 $ — Unvested stock option activity for non-employees during the year: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2015 33,333 $ 2.60 9.08 $ — Options granted — — — — Options vested (25,000 ) 2.60 — Options forfeited — — — — Outstanding June 30, 2015 8,333 $ 2.60 8.42 $ — The impact on the Company’s results of operations of recording equity-based compensation for the six months ended June 30, 2015 and 2014 was to increase general and administrative expenses by approximately $ 111,000 and $198,000 , respectively, which had no impact on earnings per share. As of June 30, 2015 and 2014, respectively, there was $269,000 and $348,000 of unrecognized equity-based compensation cost related to options granted under the Equity Incentive Plan. Generally, the Company's stock options will become recognizable within a 12 month period.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories The Company uses the lower of first-in, first-out (“FIFO”) cost or market method of accounting for inventory. Inventories consist of the following: (in thousands) June 30, December 31, 2015 2014 Inventory work-in-process, January 1 $ — $ — Production (1) 1,126 — Spoilage (117 ) — Inventory work-in-process, end of period $ 1,009 $ — (1) Commercial sales of Alferon® will not resume until new batches of commercial filled and finished product are produced and released by the FDA. We are continuing the validation of Alferon® production and production of new Alferon® API inventory commenced in February 2015. While the facility is approved by the FDA under the Biological License Application (“BLA”) for Alferon®, this status will need to be reaffirmed by an FDA pre-approval inspection. The Company will also need the FDA’s approval to release commercial product once it has submitted satisfactory stability and quality release data.

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities Marketable securities consist of mutual funds. For the three months ended June 30, 2015, it was determined that some of the Marketable Securities had other than temporary impairments of approximately $ 54,000 . There were no other than temporary impairments of Marketable Securities for the six months ended June 30, 2014. At June 30, 2015 and December 31, 2014, all securities were classified as available for sale investments and were measured as Level 1 instruments of the fair value measurements standard (see "Note 12: Fair Value"). Securities classified as available for sale consisted of: June 30, 2015 (in thousands) Securities Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-Term Investments Long Term Investments Mutual Funds $ 14,058 $ — $ (186 ) $ 13,872 $ 13,872 $ — Totals $ 14,058 $ — $ (186 ) $ 13,872 $ 13,872 $ — December 31, 2014 (in thousands) Securities Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-Term Investments Long Term Investments Mutual Funds $ 14,112 $ — $ (160 ) $ 13,952 $ 13,952 $ — Totals $ 14,112 $ — $ (160 ) $ 13,952 $ 13,952 $ — Unrealized losses on investments Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows: June 30, 2015 (in thousands) Less Than 12 Months 12 Months or Greater Totals Securities Total number in loss position Fair Values Unrealized Losses Fair Values Unrealized Losses Total Fair Value Total Unrealized Losses Mutual Funds 2 $ 5,884 $ (150 ) $ 7,988 $ (36 ) $ 13,872 $ (186 ) Totals 2 $ 5,884 $ (150 ) $ 7,988 $ (36 ) $ 13,872 $ (186 ) December 31, 2014 (in thousands) Less Than 12 Months 12 Months or Greater Totals Securities Total number in loss position Fair Values Unrealized Losses Fair Values Unrealized Losses Total Fair Value Total Unrealized Losses Mutual Funds 2 $ 5,928 $ (106 ) $ 8,024 $ (54 ) $ 13,952 $ (160 ) Totals 2 $ 5,928 $ (106 ) $ 8,024 $ (54 ) $ 13,952 $ (160 )

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consist of the following: (in thousands) June 30, 2015 December 31, 2014 Compensation $ 934 $ 1,806 Professional fees 266 404 Other expenses 271 123 Other liabilities 26 — $ 1,497 $ 2,333 The Company maintained a balance of legal fees from a law firm of $587,000 which the Company agreed to pay with the issuance of 2,105,982 shares of the Company's common stock. The Company agreed to use the Company's share price of $0.27 as of May 6, 2015 to settled the balance due; however, the Company agreed to pay the difference if the law firm receives less from the sale of the Company's common stock than the balance due within sixty days after the sale of shares is completed. The Company's share price was $0.20 as of June 30, 2015. As a result of the drop in share price, the Company accrued an additional $147,000 which has been included within the accrual for professional fees above.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]
Property and Equipment	Property and Equipment (in thousands) June 30, 2015 December 31, 2014 Land, buildings and improvements $ 11,566 $ 4,209 Furniture, fixtures, and equipment 5,527 5,307 Leasehold improvements 85 85 Total property and equipment 17,178 9,601 Less: accumulated depreciation and amortization (5,458 ) (5,000 ) Property and equipment, net $ 11,720 $ 4,601 Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from five to thirty-nine years. As of February 28, 2015, the Company had completed and put into service the construction and installation of property and equipment within its New Brunswick, NJ facility. All amounts within construction in progress were reclassed to property and equipment during the current period. As of December 31, 2014, construction in progress was $7,337,000 .

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity The Equity Incentive Plan of 2009, effective June 24, 2009 , authorizes the grant of non-qualified and incentive stock options, stock appreciation rights, restricted stock and other stock awards. A maximum of 15,000,000 shares of common stock is reserved for potential issuance pursuant to awards under the Equity Incentive Plan of 2009. Unless sooner terminated, the Equity Incentive Plan of 2009 will continue in effect for a period of 10 years from its effective date. For the six months ended June 30, 2015 and 2014, there were 800,000 and 855,000 options granted by the Company, respectively. On July 23, 2012, the Company entered into a Equity Distribution Agreement (the “EDA”) with Maxim Group LLC ("Maxim") pursuant to which the Company may sell up to $75,000,000 worth of its shares of Common Stock from time to time through Maxim, as sales agent. Under the EDA, Maxim is entitled to a fixed commission rate of 4.0% of the gross sales price of Shares sold under the EDA, up to aggregate gross proceeds of $10,000,000 , and thereafter, at a fixed commission rate of 3.0% of the gross sales price of shares sold under the EDA. Sales of the shares, if any, may be made in transactions that are deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers' transactions, including on the NYSE MKT, at market prices or as otherwise agreed with Maxim. The Company has no obligation to sell any of the Shares and may at any time suspend offers under the EDA or terminate the EDA. Up until August 4, 2015, the shares were sold pursuant to the Company's Universal Shelf Registration Statement on Form S-3, declared effective by the Securities and Exchange Commission on July 2, 2012. Since August 4, 2015, the shares are being sold pursuant to the Company's Universal Shelf Registration Statement on Form S-3, declared effective by the Securities and Exchange Commission on August 4, 2015 (the “2015 Universal Shelf”). On September 14, 2012, the Company filed a Prospectus Supplement with the SEC increasing the number of shares covered by the Prospectus from 12,000,000 to 20,000,000 shares under the EDA. On October 5, 2012, the Company filed an updated Prospectus Supplement increasing the number of shares covered by the Prospectus to 40,000,000 shares to be allocated for public sale under the Prospectus Supplement pursuant to the EDA. On December 23, 2013, the Company filed an updated Prospectus Supplement with the Securities and Exchange Commission to revise the EDA for an aggregate of 90,000,000 shares to be allocated for public sale under the Prospectus Supplement pursuant to the EDA. On March 6, 2015, the Company filed an updated Prospectus Supplement increasing the number of shares covered by the Prospectus to 117,600,000 shares. On August 5, 2015, the Company filed an updated Prospectus Supplement to reflect that sales under the EDA are now being conducted pursuant to the 2015 Universal Shelf. For the six months ended June 30, 2015, the Company had sold 38,919,883 shares of the EDA that resulted in net cash proceeds of approximately $9,293,000 after direct expenses along with commissions paid to Maxim for approximately $287,000 . The Company plans to allocate the net proceeds from the offering towards research and development, operations and general and administrative purposes related to the commercialization of Ampligen® and Alferon® related products, including, but not limited to, the following: (1) Costs to finalize the upgrade of the Alferon N Injection® manufacturing facility and to prepare for the FDA pre-approval inspections of the Ampligen® facility, (2) Manufacture of commercial product, (3) Potential new preclinical and/or clinical studies in order to gain commercial approval for Ampligen® and broader approvals for Alferon® and Alferon LDO®, (4) Working capital to build and maintain sufficient inventory by procuring raw materials, supplies and other items for the New Brunswick manufacturing facility, as well as to remunerate outside contractors for necessary services, such as, final filling and finishing operations in order to meet any anticipated demand from normal operations as well as through the possible pursuit of other disease areas and/or geographic regions that may present themselves, (5) Pursuit of potential partnering opportunities for Ampligen®, (6) Potential establishment of sales and marketing capabilities, as well as consideration towards the expansion of our manufacturing capacity, and (7) working capital for general and administrative expenses.

Cash And Cash Equivalents

Cash And Cash Equivalents	6 Months Ended
	Jun. 30, 2015
Cash and Cash Equivalents, at Carrying Value [Abstract]
Cash And Cash Equivalents	Cash And Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In 2015, the FASB issued Accounting Standards Updates (“ASU”) 2015-01 through 2015-12. These updates did not have a significant impact on the financial statements.

Funds Received From Sale Of Inc

Funds Received From Sale Of Income Tax Net Operating Losses	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Funds Received From Sale Of Income Tax Net Operating Losses	Funds Received From Sale Of Income Tax Net Operating Losses As of December 31, 2014, the Company had approximately $151,000,000 of federal net operating loss carryforwards (expiring in the years 2018 through 2034 ) available to off-set future federal taxable income. The Company also had approximately $36,000,000 of Pennsylvania state net operating loss carryforwards (expiring in the years 2018 through 2034 ) and approximately $28,000,000 of New Jersey state net operating loss carryforwards (expiring in the years 2033 through 2034 ) available to off-set future state taxable income. In January 2015, the Company effectively sold $14,291,000 of its approximately $28,000,000 of New Jersey state net operating loss carryforwards (for the year 2013) for approximately $1,374,000 . The utilization of certain state net operating loss carry-forwards may be subject to annual limitations. With no tax due for the foreseeable future, the Company has determined that the accounting for interest or penalties related to the payment of tax is not necessary at this time.

Fair Value

Fair Value	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value	Fair Value The Company is required under U.S. Generally Accepted Accounting Principles (“GAAP”) to disclose information about the fair value of all the Company’s financial instruments, whether or not these instruments are measured at fair value on the Company’s Consolidated Balance Sheets. FASB ASC 820-10-35-37 (formerly SFAS No. 157) establishes a valuation hierarchy based on the transparency of inputs used in the valuation of an asset or liability. Classification is based on the lowest level of inputs that is significant to the fair value measurement. The valuation hierarchy contains three levels: • Level 1 – Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this includes debt and equity securities that are traded in an active market. • Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market. • Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company estimates that the fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to the short-term maturities of these items. The Company also had certain warrants with a cash settlement feature in the unlikely occurrence of a Fundamental Transaction which are measured at fair value. The fair value recalculation of the Liability resulting from the issuance of the Warrants ("Call") and existence of the Fundamental Transaction ("Put") related to the May 2009 issuance, are calculated using a Monte Carlo Simulation. While the Monte Carlo Simulation is one of a number of possible pricing models, the Company has determined it to be industry accepted and fairly presented the Fair Value of the Warrants. As an additional factor to determine the Fair Value of the Put's Liability, the occurrence probability of a Fundamental Transaction event was factored into the valuation. The Company recomputed the fair value of the Warrants at the end of each quarterly reporting period. Such value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions or the numbers input based on such assumptions, the resulting fair value could be materially different. The redeemable warrants expired in May and November 2014. The balance of the redeemable warrants was $0 as of June 30, 2015 and December 31, 2014. Fair value at June 30, 2014, was estimated using the following assumptions: Underlying price per share $0.19 - $0.27 Exercise price per share $1.31 - $1.65 Risk-free interest rate 0.06% - 0.23% Expected holding period 0.38 - 1.64 yrs. Expected volatility 69.74% - 113.56% Expected dividend yield None While the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input may change from period to period (e.g., the actual historical prices input for the relevant period). As of June 30, 2014, the Company has classified the Warrants with cash settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in valuing these Warrants. The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as of June 30, 2015: (in thousands) Total Level 1 Level 2 Level 3 Assets: Marketable Securities-unrestricted $ 13,872 $ 13,872 $ — $ — The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows: Fair Value of Redeemable Warrants (in thousands) 2015 2014 Balance at January 1 $ — $ 14 Fair value adjustment at March 31 — — Balance at March 31 $ — $ 14 Fair value adjustment at June 30 — $ (1 ) Balance at June 30 $ — $ 13

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluated subsequent events through the date on which these financial statements were issued and determined that no subsequent event constituted a matter that required adjustment to the financial statements for the six months ended June 30, 2015. On August 4, 2015, the Company and Maxim Group LLC amended their July 23, 2012 EDA solely for the purpose of adding the registrant’s new registration statement on Form 3 (File No 333-205228) to the definition of “registration statement” as the old registration statement expired. On August 7, 2015, William A. Carter, M.D. resigned his position as President of the Company. The Company's Board of Directors appointed Thomas K. Equels as President of the Company, effective immediately.

Net Loss Per Share Net Loss Per

Net Loss Per Share Net Loss Per Share (Policies)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share Policy	Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Equivalent common shares, consisting of stock options and warrants which amounted to 17,228,280 and 23,730,334 shares for the six months ended June 30, 2015 and 2014, respectively, are excluded from the calculation of diluted net loss per share since their effect is anti-dilutive.

Inventories (Policy)

Inventories (Policy)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory Policy	The Company uses the lower of first-in, first-out (“FIFO”) cost or market method of accounting for inventory.

Property and Equipment (Policie

Property and Equipment (Policies)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]
Property, Plant and Equipment, Policy	Property and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, ranging from five to thirty-nine years.

Cash And Cash Equivalents (Poli

Cash And Cash Equivalents (Policies)	6 Months Ended
	Jun. 30, 2015
Cash and Cash Equivalents, at Carrying Value [Abstract]
Cash and Cash Equivalents, Policy	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Activity	Stock option for employees' activity during the six months ended June 30, 2015 is as follows: Stock option activity for employees: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2015 11,287,888 $ 1.64 4.61 $ — Granted 800,000 0.25 — — Forfeited (565,000 ) 1.75 — — Outstanding June 30, 2015 11,522,888 $ 1.54 4.71 $ — Vested and expected to vest June 30, 2015 11,522,888 $ 1.54 4.71 $ — Exercisable June 30, 2015 10,639,853 $ 1.60 4.17 $ — Unvested stock option activity for employees: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2015 710,594 $ 1.38 8.76 $ — Granted 800,000 0.25 — — Vested (627,559 ) 0.97 — — Forfeited — — — — Outstanding June 30, 2015 883,035 $ 0.65 8.97 $ — Stock option activity for non-employees: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2015 3,800,000 $ 1.36 4.75 $ — Granted — — — — Exercised — — — — Forfeited (327,000 ) 1.75 — — Outstanding June 30, 2015 3,473,000 $ 1.32 4.65 $ — Vested and expected to vest June 30, 2015 3,473,000 $ 1.32 4.65 $ — Exercisable June 30, 2015 3,464,667 $ 1.56 4.29 $ — Unvested stock option activity for non-employees during the year: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding January 1, 2015 33,333 $ 2.60 9.08 $ — Options granted — — — — Options vested (25,000 ) 2.60 — Options forfeited — — — — Outstanding June 30, 2015 8,333 $ 2.60 8.42 $ —

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: (in thousands) June 30, December 31, 2015 2014 Inventory work-in-process, January 1 $ — $ — Production (1) 1,126 — Spoilage (117 ) — Inventory work-in-process, end of period $ 1,009 $ — (1) Commercial sales of Alferon® will not resume until new batches of commercial filled and finished product are produced and released by the FDA. We are continuing the validation of Alferon® production and production of new Alferon® API inventory commenced in February 2015. While the facility is approved by the FDA under the Biological License Application (“BLA”) for Alferon®, this status will need to be reaffirmed by an FDA pre-approval inspection. The Company will also need the FDA’s approval to release commercial product once it has submitted satisfactory stability and quality release data.

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2015
Investments, Debt and Equity Securities [Abstract]
Available for sale securities	Securities classified as available for sale consisted of: June 30, 2015 (in thousands) Securities Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-Term Investments Long Term Investments Mutual Funds $ 14,058 $ — $ (186 ) $ 13,872 $ 13,872 $ — Totals $ 14,058 $ — $ (186 ) $ 13,872 $ 13,872 $ — December 31, 2014 (in thousands) Securities Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-Term Investments Long Term Investments Mutual Funds $ 14,112 $ — $ (160 ) $ 13,952 $ 13,952 $ — Totals $ 14,112 $ — $ (160 ) $ 13,952 $ 13,952 $ —
Unrealized losses on securities	Investments with continuous unrealized losses for less than 12 months and 12 months or greater and their related fair values were as follows: June 30, 2015 (in thousands) Less Than 12 Months 12 Months or Greater Totals Securities Total number in loss position Fair Values Unrealized Losses Fair Values Unrealized Losses Total Fair Value Total Unrealized Losses Mutual Funds 2 $ 5,884 $ (150 ) $ 7,988 $ (36 ) $ 13,872 $ (186 ) Totals 2 $ 5,884 $ (150 ) $ 7,988 $ (36 ) $ 13,872 $ (186 ) December 31, 2014 (in thousands) Less Than 12 Months 12 Months or Greater Totals Securities Total number in loss position Fair Values Unrealized Losses Fair Values Unrealized Losses Total Fair Value Total Unrealized Losses Mutual Funds 2 $ 5,928 $ (106 ) $ 8,024 $ (54 ) $ 13,952 $ (160 ) Totals 2 $ 5,928 $ (106 ) $ 8,024 $ (54 ) $ 13,952 $ (160 )

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses consist of the following: (in thousands) June 30, 2015 December 31, 2014 Compensation $ 934 $ 1,806 Professional fees 266 404 Other expenses 271 123 Other liabilities 26 — $ 1,497 $ 2,333 The Company maintained a balance of legal fees from a law firm of $587,000 which the Company agreed to pay with the issuance of 2,105,982 shares of the Company's common stock. The Company agreed to use the Company's share price of $0.27 as of May 6, 2015 to settled the balance due; however, the Company agreed to pay the difference if the law firm receives less from the sale of the Company's common stock than the balance due within sixty days after the sale of shares is completed. The Company's share price was $0.20 as of June 30, 2015. As a result of the drop in share price, the Company accrued an additional $147,000 which has been included within the accrual for professional fees above.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]
Property, Plant and Equipment	(in thousands) June 30, 2015 December 31, 2014 Land, buildings and improvements $ 11,566 $ 4,209 Furniture, fixtures, and equipment 5,527 5,307 Leasehold improvements 85 85 Total property and equipment 17,178 9,601 Less: accumulated depreciation and amortization (5,458 ) (5,000 ) Property and equipment, net $ 11,720 $ 4,601

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement	Fair value at June 30, 2014, was estimated using the following assumptions: Underlying price per share $0.19 - $0.27 Exercise price per share $1.31 - $1.65 Risk-free interest rate 0.06% - 0.23% Expected holding period 0.38 - 1.64 yrs. Expected volatility 69.74% - 113.56% Expected dividend yield None
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy as of June 30, 2015: (in thousands) Total Level 1 Level 2 Level 3 Assets: Marketable Securities-unrestricted $ 13,872 $ 13,872 $ — $ —
Fair Value, Liabilities Measured on Recurring Basis	The changes in Level 3 Liabilities measured at fair value on a recurring basis are summarized as follows: Fair Value of Redeemable Warrants (in thousands) 2015 2014 Balance at January 1 $ — $ 14 Fair value adjustment at March 31 — — Balance at March 31 $ — $ 14 Fair value adjustment at June 30 — $ (1 ) Balance at June 30 $ — $ 13

Basis of Presentation (Details)

Basis of Presentation (Details)	6 Months Ended
	Jun. 30, 2015subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of domestic subsidiaries (subsidiaries)	3

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Stock options and warrants excluded from calculation of diluted net loss per share (shares)	17,228,280	23,730,334

Equity-Based Compensation (Valu

Equity-Based Compensation (Valuation Assumptions) (Details) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Method used	Black-Scholes-Merton
Options or equity warrants granted in period (shares)	800,000	855,000

Equity-Based Compensation (Opti

Equity-Based Compensation (Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options or equity warrants granted in period (shares)	800,000	855,000
Share-based Compensation Arrangement By Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]
Stock issued during period, value	$ 111
Total compensation cost not yet recognized	$ 269	$ 348
Employee Vested Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding (shares)	11,287,888
Number of options granted (shares)	800,000
Number of options forfeited (shares)	(565,000)
Number of options outstanding (shares)	11,522,888		11,287,888
Number of options vested and expected to vest, outstanding (shares)	11,522,888
Number of options vested and expected to vest, exercisable (shares)	10,639,853
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Options Outstanding (usd per share)	$ 1.64
Weighted Average Exercise Price, Options Granted (usd per share)	0.25
Weighted Average Exercise Price, Options Forfeited (usd per share)	1.75
Weighted Average Exercise Price, Options Outstanding (usd per share)	1.54		$ 1.64
Weighted Average Exercise Price, Options Vested and Expected to Vest, Outstanding (usd per share)	1.54
Weighted Average Exercise Price, Options Vested and Expected to Vest, Exercisable (usd per share)	$ 1.60
Share-based Compensation Arrangement By Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Roll Forward]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	4 years 8 months 15 days		4 years 7 months 9 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	4 years 8 months 15 days		4 years 7 months 9 days
Weighted Average Remaining Contractual Term (Years), Options vested and expected to vest	4 years 8 months 15 days
Weighted Average Remaining Contractual Term (Years), Options exercisable	4 years 2 months 2 days
Share-based Compensation Arrangement By Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]
Aggregate Intrinsic Value, Options Outstanding	$ 0
Aggregate Intrinsic Value, Options Granted	0
Aggregate Intrinsic Value, Options Forfeited	0
Aggregate Intrinsic Value, Options Outstanding	0		$ 0
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Outstanding	0
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Exercisable	$ 0
Employee Nonvested Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding (shares)	710,594
Number of options granted (shares)	800,000
Number of options vested (shares)	(627,559)
Number of options forfeited (shares)	0
Number of options outstanding (shares)	883,035		710,594
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Options Outstanding (usd per share)	$ 1.38
Weighted Average Exercise Price, Options Granted (usd per share)	0.25
Weighted Average Exercise Price, Options Vested (usd per share)	0.97
Weighted Average Exercise Price, Options Forfeited (usd per share)	0
Weighted Average Exercise Price, Options Outstanding (usd per share)	$ 0.65		$ 1.38
Share-based Compensation Arrangement By Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Roll Forward]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 11 months 19 days		8 years 9 months 4 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 11 months 19 days		8 years 9 months 4 days
Share-based Compensation Arrangement By Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]
Aggregate Intrinsic Value, Options Outstanding	$ 0
Aggregate Intrinsic Value, Options Granted	0
Aggregate Intrinsic Value, Options Vested	0
Aggregate Intrinsic Value, Options Forfeited	0
Aggregate Intrinsic Value, Options Outstanding	$ 0		$ 0
Nonemployee Vested Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding (shares)	3,800,000
Number of options granted (shares)	0
Number of options exercised (shares)	0
Number of options forfeited (shares)	(327,000)
Number of options outstanding (shares)	3,473,000		3,800,000
Number of options vested and expected to vest, outstanding (shares)	3,473,000
Number of options vested and expected to vest, exercisable (shares)	3,464,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Options Outstanding (usd per share)	$ 1.36
Weighted Average Exercise Price, Options Granted (usd per share)	0
Weighted Average Exercise Price, Options Exercised (usd per share)	0
Weighted Average Exercise Price, Options Forfeited (usd per share)	1.75
Weighted Average Exercise Price, Options Outstanding (usd per share)	1.32		$ 1.36
Weighted Average Exercise Price, Options Vested and Expected to Vest, Outstanding (usd per share)	1.32
Weighted Average Exercise Price, Options Vested and Expected to Vest, Exercisable (usd per share)	$ 1.56
Share-based Compensation Arrangement By Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Roll Forward]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	4 years 7 months 23 days		4 years 9 months
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	4 years 7 months 23 days		4 years 9 months
Weighted Average Remaining Contractual Term (Years), Options vested and expected to vest	4 years 7 months 23 days
Weighted Average Remaining Contractual Term (Years), Options exercisable	4 years 3 months 15 days
Share-based Compensation Arrangement By Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]
Aggregate Intrinsic Value, Options Outstanding	$ 0
Aggregate Intrinsic Value, Options Granted	0
Aggregate Intrinsic Value, Options Exercised	0
Aggregate Intrinsic Value, Options Forfeited	0
Aggregate Intrinsic Value, Options Outstanding	0		$ 0
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Outstanding	0
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Exercisable	$ 0
Nonemployee Nonvested Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding (shares)	33,333
Number of options granted (shares)	0
Number of options vested (shares)	(25,000)
Number of options forfeited (shares)	0
Number of options outstanding (shares)	8,333		33,333
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Options Outstanding (usd per share)	$ 2.60
Weighted Average Exercise Price, Options Granted (usd per share)	0
Weighted Average Exercise Price, Options Vested (usd per share)	2.60
Weighted Average Exercise Price, Options Forfeited (usd per share)	0
Weighted Average Exercise Price, Options Outstanding (usd per share)	$ 2.60		$ 2.60
Share-based Compensation Arrangement By Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Roll Forward]
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 4 months 31 days		9 years 1 month
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 4 months 31 days		9 years 1 month
Share-based Compensation Arrangement By Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]
Aggregate Intrinsic Value, Options Outstanding	$ 0
Aggregate Intrinsic Value, Options Granted	0
Aggregate Intrinsic Value, Options Vested	0
Aggregate Intrinsic Value, Options Forfeited	0
Aggregate Intrinsic Value, Options Outstanding	0		$ 0
General and Administrative Expense [Member]
Share-based Compensation Arrangement By Share-based Payment Award, Options, Aggregate Intrinsic Value [Roll Forward]
Stock issued during period, value	$ 111	$ 198

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Inventory Work-in-Process [Roll Forward]
Inventory, work-in-process, beginning of period	$ 0	$ 0
Production	1,126	0
Spoilage	(117)	0
Inventory work-in-process, end of period	$ 1,009	$ 0

Marketable Securities (Availabl

Marketable Securities (Available for Sale Securities) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 14,058	$ 14,112
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(186)	(160)
Fair Value	13,872	13,952
Short-Term Investments	13,872	13,952
Long Term Investments	0	0
Mutual Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	14,058	14,112
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(186)	(160)
Fair Value	13,872	13,952
Short-Term Investments	13,872	13,952
Long Term Investments	$ 0	$ 0

Marketable Securities (Details)

Marketable Securities (Details)	6 Months Ended
	Jun. 30, 2015USD ($)investment	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)investment
Schedule of Available-for-sale Securities [Line Items]
Other than temporary impairments of marketable securities	$ 54,000	$ 0
Total number in loss position (investments) | investment	2		2
Less than twelve months - fair values	$ 5,884,000		$ 5,928,000
Less than twelve months - unrealized losses	(150,000)		(106,000)
Twelve months or greater - fair values	7,988,000		8,024,000
Twelve months or greater - unrealized losses	(36,000)		(54,000)
Total Fair Value	13,872,000		13,952,000
Total Unrealized Losses	$ (186,000)		$ (160,000)
Mutual Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Total number in loss position (investments) | investment	2		2
Less than twelve months - fair values	$ 5,884,000		$ 5,928,000
Less than twelve months - unrealized losses	(150,000)		(106,000)
Twelve months or greater - fair values	7,988,000		8,024,000
Twelve months or greater - unrealized losses	(36,000)		(54,000)
Total Fair Value	13,872,000		13,952,000
Total Unrealized Losses	$ (186,000)		$ (160,000)

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Compensation	$ 934	$ 1,806
Professional fees	266	404
Other expenses	271	123
Other liabilities	26	0
Total Accrued Expenses	$ 1,497	$ 2,333

Accrued Expenses Accrued Expens

Accrued Expenses Accrued Expenses Settled with Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	May. 06, 2015	Jun. 30, 2015	Dec. 31, 2014
Schedule of Capitalization, Equity [Line Items]
Legal fees		$ 266	$ 404
Common Stock [Member]
Schedule of Capitalization, Equity [Line Items]
Shares to settle accounts payable (shares)	2,105,982	2,558,779
Share price (usd per share)	$ 0.27	$ 0.20
Accrued Legal Fees [Member]
Schedule of Capitalization, Equity [Line Items]
Legal fees	$ 587	$ 147

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 17,178	$ 9,601
Less: accumulated depreciation and amortization	(5,458)	(5,000)
Property and equipment, net	11,720	4,601
Construction in progress	0	7,337
Land, buildings and improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	11,566	4,209
Furniture, fixtures, and equipment[Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	5,527	5,307
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 85	$ 85
Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	39 years

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Equity Incentive Plan of 2009 [Member] - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Date established	Jun. 24, 2009
Number of shares authorized (shares)	15,000,000
Number of options granted (shares)	800,000	855,000
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award requisite service period	10 years

Stockholders' Equity (Equity Di

Stockholders' Equity (Equity Distribution Agreement) (Details) - Maxim 2012 Agreement [Member] - USD ($)	Mar. 06, 2015	Dec. 23, 2013	Oct. 05, 2012	Sep. 14, 2012	Jul. 23, 2012	Jun. 30, 2015
Class of Stock [Line Items]
Maximum dollar amount of shares under the EDA					$ 75,000,000
Fixed commission rate for gross proceeds $10,000,000 or less (percent)					4.00%
Gross proceeds from common stock, threshold					$ 10,000,000
Fixed commission rate for gross proceeds in excess of $10,000,000 (percent)					3.00%
Number of shares sold under equity distribution agreement						38,919,883
Cash proceeds from shares sold under equity distribution agreement						$ 9,293,000
Commissions paid on shares sold under equity distribution agreement						$ 287,000
October 5, 2012 Prospectus Supplement Increased Offering [Member]
Class of Stock [Line Items]
Number of shares to be sold under the equity distribution agreement			40,000,000
December 23, 2013 Prospectus Supplement Increased Offering [Member]
Class of Stock [Line Items]
Number of shares to be sold under the equity distribution agreement		90,000,000
March 6, 2015 Prospectus Supplement Increased Offering [Member]
Class of Stock [Line Items]
Number of shares to be sold under the equity distribution agreement	117,600,000
Minimum [Member] | September 14, 2012 Prospectus Supplement Increased Offering [Member]
Class of Stock [Line Items]
Number of shares to be sold under the equity distribution agreement				12,000,000
Maximum [Member] | September 14, 2012 Prospectus Supplement Increased Offering [Member]
Class of Stock [Line Items]
Number of shares to be sold under the equity distribution agreement				20,000,000

Funds Received From Sale Of I43

Funds Received From Sale Of Income Tax Net Operating Losses (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Funds received from sale of income tax net operating losses	$ 1,374	$ 0	$ 0	$ 1,374	$ 1,126
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards						$ 151,000
Pennsylvania [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards						36,000
New Jersey [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards						$ 28,000
Operating loss carryforwards, amount of NOL carryforwards sold	$ 14,291

Fair Value (Fair Value Assumpti

Fair Value (Fair Value Assumptions) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Redeemable warrants		$ 0	$ 0
Risk-free interest rate, minimum	0.06%
Risk-free interest rate, maximum	0.23%
Expected volatility, minimum	69.74%
Expected volatility, maximum	113.56%
Expected dividend yield	0.00%
Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Underlying price per share	$ 0.19
Exercise price per share	$ 1.31
Expected holding period	4 months 17 days
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Underlying price per share	$ 0.27
Exercise price per share	$ 1.65
Expected holding period	1 year 7 months 21 days

Fair Value (Assets and Liabilit

Fair Value (Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities - Unrestricted	$ 13,872	$ 13,952
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities - Unrestricted	13,872
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities - Unrestricted	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities - Unrestricted	0
Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities - Unrestricted	$ 13,872

Fair Value (Changes in Level 3

Fair Value (Changes in Level 3 Liabilities) (Details) - Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance, beginning	$ 0	$ 0	$ 14	$ 14
Fair value adjustment	0	0	(1)	0
Balance, ending	$ 0	$ 0	$ 13	$ 14